Abstract
Infection with HBV and its satellite virus HDV remain a significant global health issue due to their involvement in hepatic and extrahepatic diseases, including B cell non-Hodgkin’s lymphoma (BNHL). Clinical and epidemiological evidence support a causal role for HBV in BNHL development, although mechanistic insight is lacking and the role of HDV infection in this process is unknown. To help elucidate viral drivers of B cell transformation, we performed RNA-sequencing on peripheral B cells from patients with HBV mono-infection, HBV/HDV co-infection, HBV/HDV-associated BNHL, BNHL without viral infection, and healthy donors. In this way, we sought to identify unique and shared transcriptional profiles associated with viral infection and transformation. Our data suggest dysregulated epigenetic and miRNA-mediated regulatory gene expression may be a potential common pathway for lymphomagenesis among viral- and non-viral-associated lymphoma. We also observed wide-spread upregulation of snoRNAs in B cells from virally infected patients, supporting a role for these non-coding RNAs in viral infection and, potentially, viral-associated lymphomagenesis. These results have identified novel areas for future functional studies on the effect of HBV and HDV infection on B cell activity and present additional therapeutic strategies that may benefit both viral- and non-viral associated BNHL.
Similar content being viewed by others
Data availability
The datasets generated and analyzed during the current study are available in the GEO repository, [https://www.ncbi.nlm.nih.gov/geo/](https:/www.ncbi.nlm.nih.gov/geo), under accession number GSE279755. Additional information and files are available on reasonable request.
References
Global hepatitis report 2024: action for access in low- and middle-income countries. (World Health Organization, Geneva, 2024).
Mentha, N., Clement, S., Negro, F. & Alfaiate, D. A review on hepatitis D: From virology to new therapies. J. Adv. Res. 17, 3–15. https://doi.org/10.1016/j.jare.2019.03.009 (2019).
Rosenberg, M. et al. Hepatitis B Virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities. Front. Oncol. 13, 1275800. https://doi.org/10.3389/fonc.2023.1275800 (2023).
Ren, W. et al. Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. Blood Adv. 6, 2731–2744. https://doi.org/10.1182/bloodadvances.2021006410 (2022).
Ren, W. et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood 131, 2670–2681. https://doi.org/10.1182/blood-2017-11-817601 (2018).
Svicher, V. et al. New insights into hepatitis B virus lymphotropism: Implications for HBV-related lymphomagenesis. Front. Oncol. 13, 1143258. https://doi.org/10.3389/fonc.2023.1143258 (2023).
Coffin, C. S., Mulrooney-Cousins, P. M. & Michalak, T. I. Hepadnaviral lymphotropism and its relevance to HBV persistence and pathogenesis. Front. Microbiol. 12, 695384. https://doi.org/10.3389/fmicb.2021.695384 (2021).
Li, M. et al. Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma. Int. J. Cancer 147, 2199–2209. https://doi.org/10.1002/ijc.33027 (2020).
Wang, Y. et al. Capable infection of hepatitis B virus in diffuse large B-cell lymphoma. J. Cancer 9, 1575–1581. https://doi.org/10.7150/jca.24384 (2018).
Dashtseren, B. et al. Endemic prevalence of hepatitis B and C in Mongolia: A nationwide survey amongst Mongolian adults. J. Viral. Hepat. 24, 759–767. https://doi.org/10.1111/jvh.12697 (2017).
Chen, X. et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. Hepatology 66, 1739–1749. https://doi.org/10.1002/hep.28957 (2017).
Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43, 1317–1325. https://doi.org/10.1002/hep.21178 (2006).
Wen, Y. et al. The regulators of BCR signaling during B cell activation. Blood Sci. 1, 119–129. https://doi.org/10.1097/BS9.0000000000000026 (2019).
Khiem, D., Cyster, J. G., Schwarz, J. J. & Black, B. L. A p38 MAPK-MEF2C pathway regulates B-cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 105, 17067–17072. https://doi.org/10.1073/pnas.0804868105 (2008).
Li, T. Y., Yang, Y., Zhou, G. & Tu, Z. K. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J. Gastroenterol. 25, 3527–3537. https://doi.org/10.3748/wjg.v25.i27.3527 (2019).
Henning, A. N. et al. Peripheral B cells from patients with hepatitis C virus-associated lymphoma exhibit clonal expansion and an anergic-like transcriptional profile. iScience 26, 105801. https://doi.org/10.1016/j.isci.2022.105801 (2023).
Charles, E. D. et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 117, 5425–5437. https://doi.org/10.1182/blood-2010-10-312942 (2011).
Isnardi, I. et al. Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood 115, 5026–5036. https://doi.org/10.1182/blood-2009-09-243071 (2010).
Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381. https://doi.org/10.1038/nmeth.3364 (2015).
Bolotin, D. A. et al. Antigen receptor repertoire profiling from RNA-seq data. Nat. Biotechnol. 35, 908–911. https://doi.org/10.1038/nbt.3979 (2017).
Deng, L. et al. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget 6, 25061–25073. https://doi.org/10.18632/oncotarget.4677 (2015).
Niaz, S. & Hussain, M. U. Role of GW182 protein in the cell. Int. J. Biochem. Cell Biol. 101, 29–38. https://doi.org/10.1016/j.biocel.2018.05.009 (2018).
Ryu, I., Park, J. H., An, S., Kwon, O. S. & Jang, S. K. eIF4GI facilitates the MicroRNA-mediated gene silencing. PLoS ONE 8, e55725. https://doi.org/10.1371/journal.pone.0055725 (2013).
Huang, Z. H., Du, Y. P., Wen, J. T., Lu, B. F. & Zhao, Y. snoRNAs: functions and mechanisms in biological processes, and roles in tumor pathophysiology. Cell Death Discov. 8, 259. https://doi.org/10.1038/s41420-022-01056-8 (2022).
Dong, H. J., Zhang, R., Kuang, Y. & Wang, X. J. Selective regulation in ribosome biogenesis and protein production for efficient viral translation. Arch. Microbiol. 203, 1021–1032. https://doi.org/10.1007/s00203-020-02094-5 (2021).
Iarovaia, O. V., Ioudinkova, E. S., Velichko, A. K. & Razin, S. V. Manipulation of cellular processes via nucleolus Hijaking in the course of viral infection in mammals. Cells https://doi.org/10.3390/cells10071597 (2021).
Fafard-Couture, E., Jacques, P. E. & Scott, M. S. Motif conservation, stability, and host gene expression are the main drivers of snoRNA expression across vertebrates. Genome Res. 33, 525–540. https://doi.org/10.1101/gr.277483.122 (2023).
Fafard-Couture, E., Bergeron, D., Couture, S., Abou-Elela, S. & Scott, M. S. Annotation of snoRNA abundance across human tissues reveals complex snoRNA-host gene relationships. Genome Biol. 22, 172. https://doi.org/10.1186/s13059-021-02391-2 (2021).
Dupuis-Sandoval, F., Poirier, M. & Scott, M. S. The emerging landscape of small nucleolar RNAs in cell biology. Wiley Interdiscip. Rev. RNA 6, 381–397. https://doi.org/10.1002/wrna.1284 (2015).
Wu, L. et al. Clinical significance of C/D box small nucleolar RNA U76 as an oncogene and a prognostic biomarker in hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 42, 82–91. https://doi.org/10.1016/j.clinre.2017.04.018 (2018).
Chen, L. et al. SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma. Sci. Rep. 5, 8588. https://doi.org/10.1038/srep08588 (2015).
Bao, Y. & Cao, X. Epigenetic control of B cell development and B-Cell-related immune disorders. Clin. Rev. Allergy Immunol. 50, 301–311. https://doi.org/10.1007/s12016-015-8494-7 (2016).
Jiang, Y., Dominguez, P. M. & Melnick, A. M. The many layers of epigenetic dysfunction in B-cell lymphomas. Curr. Opin. Hematol. 23, 377–384. https://doi.org/10.1097/MOH.0000000000000249 (2016).
Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830–837. https://doi.org/10.1038/ng.892 (2011).
Cao, B. et al. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics. BMC Med. Genomics 17, 84. https://doi.org/10.1186/s12920-024-01866-y (2024).
Candelaria, M. et al. Characterizing the mutational landscape of diffuse large B-cell lymphoma in a prospective cohort of Mexican patients. Int. J. Mol. Sci. https://doi.org/10.3390/ijms25179328 (2024).
Zeisel, M. B., Guerrieri, F. & Levrero, M. Host epigenetic alterations and hepatitis B virus-associated hepatocellular carcinoma. J. Clin. Med. https://doi.org/10.3390/jcm10081715 (2021).
Koumbi, L. & Karayiannis, P. The epigenetic control of hepatitis B virus modulates the outcome of infection. Front. Microbiol. 6, 1491. https://doi.org/10.3389/fmicb.2015.01491 (2015).
Nsengimana, B. et al. Processing body (P-body) and its mediators in cancer. Mol. Cell. Biochem. 477, 1217–1238. https://doi.org/10.1007/s11010-022-04359-7 (2022).
Riggs, C. L., Kedersha, N., Ivanov, P. & Anderson, P. Mammalian stress granules and P bodies at a glance. J. Cell. Sci. https://doi.org/10.1242/jcs.242487 (2020).
Perez-Vilaro, G. et al. Hepatitis C virus infection inhibits P-body granule formation in human livers. J. Hepatol. 62, 785–790. https://doi.org/10.1016/j.jhep.2014.11.018 (2015).
Park, C., Qian, W. & Zhang, J. Genomic evidence for elevated mutation rates in highly expressed genes. EMBO Rep. 13, 1123–1129. https://doi.org/10.1038/embor.2012.165 (2012).
Ahuja, R., Kapoor, N. R. & Kumar, V. The HBx oncoprotein of hepatitis B virus engages nucleophosmin to promote rDNA transcription and cellular proliferation. Biochim. Biophys. Acta 1783–1795, 2015. https://doi.org/10.1016/j.bbamcr.2015.04.012 (1853).
Huang, W. H., Yung, B. Y., Syu, W. J. & Lee, Y. H. The nucleolar phosphoprotein B23 interacts with hepatitis delta antigens and modulates the hepatitis delta virus RNA replication. J. Biol. Chem. 276, 25166–25175. https://doi.org/10.1074/jbc.M010087200 (2001).
Huang, W. H., Chen, Y. S. & Chen, P. J. Nucleolar targeting of hepatitis delta antigen abolishes its ability to initiate viral antigenomic RNA replication. J. Virol. 82, 692–699. https://doi.org/10.1128/JVI.01155-07 (2008).
Shen, L. et al. Involvement of the oncogenic small nucleolar RNA SNORA24 in regulation of p53 stability in colorectal cancer. Cell Biol. Toxicol. 39, 1377–1394. https://doi.org/10.1007/s10565-022-09765-7 (2023).
Su, X. et al. The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53. Cell. Death Differ. 28, 2450–2464. https://doi.org/10.1038/s41418-021-00762-7 (2021).
Yu, F. et al. p53 Represses the Oncogenic Sno-MiR-28 Derived from a SnoRNA. PLoS ONE 10, e0129190. https://doi.org/10.1371/journal.pone.0129190 (2015).
Bao, H. J. et al. Box C/D snoRNA SNORD89 influences the occurrence and development of endometrial cancer through 2′-O-methylation modification of Bim. Cell Death Discov. 8, 309. https://doi.org/10.1038/s41420-022-01102-5 (2022).
Lu, B. et al. C/D box small nucleolar RNA SNORD104 promotes endometrial cancer by regulating the 2′-O-methylation of PARP1. J. Transl. Med. 20, 618. https://doi.org/10.1186/s12967-022-03802-z (2022).
Wu, W. et al. SNORD60 promotes the tumorigenesis and progression of endometrial cancer through binding PIK3CA and regulating PI3K/AKT/mTOR signaling pathway. Mol. Carcinog. 62, 413–426. https://doi.org/10.1002/mc.23495 (2023).
Yuan, X., Huang, C. & Ran, Y. Exosome in HBV infection: current concepts and future perspectives. Front. Cell. Infect. Microbiol. 15, 1547525. https://doi.org/10.3389/fcimb.2025.1547525 (2025).
Harris, N. L. et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84, 1361–1392 (1994).
Swerdlow SH, C. E., Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. (IARC, Lyon, 2017).
Karatayli, E. et al. A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control. J. Clin. Virol. 60, 11–15. https://doi.org/10.1016/j.jcv.2014.01.021 (2014).
Huang, R., Liao, X. & Li, Q. Integrative genomic analysis of a novel small nucleolar RNAs prognostic signature in patients with acute myelocytic leukemia. Math. Biosci. Eng. 19, 2424–2452. https://doi.org/10.3934/mbe.2022112 (2022).
Schulten, H. J. et al. Comprehensive molecular biomarker identification in breast cancer brain metastases. J. Transl. Med. 15, 269. https://doi.org/10.1186/s12967-017-1370-x (2017).
Taghizadeh, E., Heydarheydari, S., Saberi, A., JafarpoorNesheli, S. & Rezaeijo, S. M. Breast cancer prediction with transcriptome profiling using feature selection and machine learning methods. BMC Bioinform. 23, 410. https://doi.org/10.1186/s12859-022-04965-8 (2022).
Wang, B. et al. A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients. Mol. Cancer 21, 22. https://doi.org/10.1186/s12943-022-01504-0 (2022).
Krishnan, P. et al. Profiling of small nucleolar RNAs by next generation sequencing: potential new players for breast cancer prognosis. PLoS ONE 11, e0162622. https://doi.org/10.1371/journal.pone.0162622 (2016).
He, J. Y. et al. Small nucleolar RNA, C/D Box 16 (SNORD16) acts as a potential prognostic biomarker in colon cancer. Dose Response 18, 1559325820917829. https://doi.org/10.1177/1559325820917829 (2020).
Tosar, J. P., Garcia-Silva, M. R. & Cayota, A. Circulating SNORD57 rather than piR-54265 is a promising biomarker for colorectal cancer: common pitfalls in the study of somatic piRNAs in cancer. RNA 27, 403–410. https://doi.org/10.1261/rna.078444.120 (2021).
Huang, L. et al. Prognostic value of small nucleolar RNAs (snoRNAs) for colon adenocarcinoma based on RNA sequencing data. Pathol. Res. Pract. 216, 152937. https://doi.org/10.1016/j.prp.2020.152937 (2020).
Li, M. W. et al. Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B-cell lymphoma. Cancer Med. 12, 3812–3829. https://doi.org/10.1002/cam4.5115 (2023).
Ding, Y. et al. Downregulation of snoRNA SNORA52 and its clinical significance in hepatocellular carcinoma. Biomed. Res. Int. 2021, 7020637. https://doi.org/10.1155/2021/7020637 (2021).
Xie, Q. et al. Identification of key snoRNAs serves as biomarkers for hepatocellular carcinoma by bioinformatics methods. Medicine (Baltimore) https://doi.org/10.1097/MD.0000000000030813 (2022).
Lopez-Corral, L. et al. Genomic analysis of high-risk smoldering multiple myeloma. Haematologica 97, 1439–1443. https://doi.org/10.3324/haematol.2011.060780 (2012).
Zhang, L., Xin, M. & Wang, P. Identification of a novel snoRNA expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on RNA sequencing dataset. Math. Biosci. Eng. 18, 7837–7860. https://doi.org/10.3934/mbe.2021389 (2021).
Gao, L. et al. Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep sequencing. Int. J. Cancer 136, E623-629. https://doi.org/10.1002/ijc.29169 (2015).
Liao, J. et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol. Cancer 9, 198. https://doi.org/10.1186/1476-4598-9-198 (2010).
Dong, X. et al. Tumor-educated platelet SNORD55 as a potential biomarker for the early diagnosis of non-small cell lung cancer. Thorac. Cancer 12, 659–666. https://doi.org/10.1111/1759-7714.13823 (2021).
Zhou, H. et al. Identification of small nucleolar RNA SNORD60 as a potential biomarker and its clinical significance in lung adenocarcinoma. Biomed. Res. Int. 2022, 5501171. https://doi.org/10.1155/2022/5501171 (2022).
Wang, K. et al. Plasma SNORD83A as a potential biomarker for early diagnosis of non-small-cell lung cancer. Future Oncol. 18, 821–832. https://doi.org/10.2217/fon-2021-1278 (2022).
Zhu, W. et al. SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway. J. Transl. Med. 17, 259. https://doi.org/10.1186/s12967-019-2005-1 (2019).
Kitagawa, T. et al. Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer. Mol. Oncol. 13, 212–227. https://doi.org/10.1002/1878-0261.12398 (2019).
Nikas, J. B. & Nikas, E. G. Genome-wide DNA methylation model for the diagnosis of prostate cancer. ACS Omega 4, 14895–14901. https://doi.org/10.1021/acsomega.9b01613 (2019).
Zhang, Y. et al. A three-snoRNA signature: SNORD15A, SNORD35B and SNORD60 as novel biomarker for renal cell carcinoma. Cancer Cell Int. 23, 136. https://doi.org/10.1186/s12935-023-02978-8 (2023).
Wang, L. Y. et al. Characterization the prognosis role and effects of snoRNAs in melanoma patients. Exp. Dermatol. 33, e14944. https://doi.org/10.1111/exd.14944 (2024).
Yi, Q. & Zou, W. J. A novel four-snoRNA signature for predicting the survival of patients with uveal melanoma. Mol. Med. Rep. 19, 1294–1301. https://doi.org/10.3892/mmr.2018.9766 (2019).
Gong, J. et al. A pan-cancer analysis of the expression and clinical relevance of small nucleolar RNAs in human cancer. Cell Rep. 21, 1968–1981. https://doi.org/10.1016/j.celrep.2017.10.070 (2017).
Cui, C. et al. NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. Oncogene 40, 909–921. https://doi.org/10.1038/s41388-020-01570-y (2021).
Faucher-Giguere, L. et al. High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival. NAR Cancer https://doi.org/10.1093/narcan/zcab050 (2022).
Xu, A. et al. LncRNA H19 suppresses osteosarcomagenesis by regulating snoRNAs and DNA repair protein complexes. Front. Genet. 11, 611823. https://doi.org/10.3389/fgene.2020.611823 (2020).
Chen, F., Zheng, Y., Zhou, H. & Li, C. The regulatory role of SNORD35A in pancreatic cancer involves the HGF/C-met pathway. Cancer Biother. Radiopharm 39, 211–222. https://doi.org/10.1089/cbr.2022.0018 (2024).
Xu, B. et al. SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma. Oncotarget 8, 43953–43966. https://doi.org/10.18632/oncotarget.16693 (2017).
McMahon, M. et al. A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS. Elife https://doi.org/10.7554/eLife.48847 (2019).
Che, Y. et al. KRAS regulation by small non-coding RNAs and SNARE proteins. Nat. Commun. 10, 5118. https://doi.org/10.1038/s41467-019-13106-4 (2019).
Patil, P. et al. scaRNAs regulate splicing and vertebrate heart development. Biochim. Biophys. Acta 1619–1629, 2015. https://doi.org/10.1016/j.bbadis.2015.04.016 (1852).
Falaleeva, M. et al. Dual function of C/D box small nucleolar RNAs in rRNA modification and alternative pre-mRNA splicing. Proc. Natl. Acad. Sci. U. S. A. 113, E1625-1634. https://doi.org/10.1073/pnas.1519292113 (2016).
Huang, C. et al. A snoRNA modulates mRNA 3′ end processing and regulates the expression of a subset of mRNAs. Nucleic Acids Res. 45, 8647–8660. https://doi.org/10.1093/nar/gkx651 (2017).
Sharma, E., Sterne-Weiler, T., O’Hanlon, D. & Blencowe, B. J. Global mapping of human RNA-RNA interactions. Mol. Cell 62, 618–626. https://doi.org/10.1016/j.molcel.2016.04.030 (2016).
Chabronova, A. et al. Depletion of SNORA33 abolishes psi of 28S–U4966 and affects the ribosome translational apparatus. Int. J. Mol. Sci. https://doi.org/10.3390/ijms241612578 (2023).
Acknowledgements
The authors thank all patients for their participation in this study.
Funding
Open access funding provided by the National Institutes of Health. This work was supported by funding provided by an NIAID-NCI research grant (Viral Hepatitis and Liver Cancer Research: U.S.-Mongolia Pilot Collaborative Award Program, 2016) and by the Intramural Research Program of the NIH Clinical Center (1ZIACL002121-11). The contributions of the NIH authors are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the authors and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.
Author information
Authors and Affiliations
Contributions
ANH performed data analysis, generated all article figures, and wrote the article. VDG and HJA conceived and designed the study; VDG supervised the research study; JP, LP, SM, OC, DOA, KR and RB supported the experimental work; SM supported the final review and editing; DB, MB, ND, DY, DD, and KB recruited participants, executed clinical protocols, and collected samples and clinical data. All co-authors critically reviewed the article.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Henning, A.N., Budeebazar, M., Boldbaatar, D. et al. Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription. Sci Rep (2026). https://doi.org/10.1038/s41598-026-35041-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-35041-3


